Peru
Tuberculosis profile
Population  2013 30 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.3 (1.7–3) 7.7 (5.7–10)
Mortality (HIV+TB only) 0.42 (0.31–0.54) 1.4 (1–1.8)
Prevalence  (includes HIV+TB) 50 (23–86) 164 (77–283)
Incidence  (includes HIV+TB) 38 (33–43) 124 (110–142)
Incidence (HIV+TB only) 2.3 (2–2.6) 7.5 (6.6–8.5)
Case detection, all forms (%) 79 (69–89)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 3.9 (3.6–4.2) 35 (33–37)
MDR-TB cases among notified pulmonary
TB cases
850 (790–930) 1 200 (1 100–1 300)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 17 435   1 802
Pulmonary, clinically diagnosed 4 481   289
Extrapulmonary 5 588   136
       
Total new and relapse 29 731    
Previously treated, excluding relapses 1 321    
Total cases notified 31 052    
Among 27 504 new cases:
1 814 (7%) cases aged under 15 years; male:female ratio: 1.6
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 13 601 (78%) 3 541 (100%) 20 459
Laboratory-confirmed RR-/MDR-TB cases     1 462
Patients started on MDR-TB treatment     1 425
TB/HIV 2013 Number (%)
TB patients with known HIV status 20 608 (66)
HIV-positive TB patients 1 243 (6)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 440 (35)
HIV-positive TB patients on antiretroviral therapy (ART) 795 (64)
HIV-positive people screened for TB    
HIV-positive people provided with IPT 1 115  
Treatment success rate (%)
New cases registered in 2012 67
Previously treated cases registered in 2012  
HIV-positive TB cases, all types, registered in 2012 67
RR-/MDR-TB cases started on second-line treatment in 2011 54
XDR-TB cases started on second-line treatment in 2011 30
Laboratories 2013  
Smear (per 100 000 population) 5.3
Culture (per 5 million population) 9.9
Drug susceptibility testing (per 5 million population) 1.3
Sites performing Xpert MTB/RIF  
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 181
% Funded domestically 26%
% Funded internationally  
% Unfunded 74%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-03-06 Data: www.who.int/tb/data